UK Opens Door to Space-Based Drug Manufacturing With New Regulatory Roadmap

The UK government has launched an ambitious initiative to accelerate the development and commercialisation of medicines manufactured in space, removing regulatory barriers that have previously held back this emerging field. The coordinated package of measures, announced on 5 March 2026 at Space-Comm Expo at ExCeL London, brings together the UK Space Agency, the Medicines and Healthcare products Regulatory Agency (MHRA), the Regulatory Innovation Office (RIO) within the Department for Science, Innovation and Technology, and the Civil Aviation Authority (CAA) to create a clear pathway from orbital manufacturing to patient access on Earth.

This world-first regulatory roadmap addresses a significant gap in the pharmaceutical supply chain. Until now, companies developing medicines in microgravity—the weightless environment found in space—have faced uncertainty about how existing UK medicines regulations would apply to their products. The unique conditions in orbit allow scientists to grow protein crystals with greater precision than is possible on Earth, potentially transforming the manufacture of complex biological medicines including cancer treatments.

The MHRA, the UK’s medicines regulator, is adapting its existing 2025 framework for small-scale and mobile manufacturing units to accommodate space-based production. Rather than requiring traditional factory settings, companies developing medicines in orbit can now meet rigorous safety standards through alternative compliance pathways. This approach ensures that drugs manufactured in space will meet exactly the same safety, quality and efficacy standards as medicines produced in conventional facilities.

“The UK is well placed to enable safe, cutting-edge innovation in space-enabled biomanufacturing,” said Lawrence Tallon, Chief Executive of the MHRA. “Our existing medicines regulations already support advanced and novel manufacturing approaches, including those that take advantage of microgravity. Through joint case studies and early scientific and regulatory advice, the MHRA is helping to shape a clear pathway from in-orbit manufacture to patient access—supporting innovation whilst maintaining the highest standards of safety, quality and patient protection.”

The regulatory package includes four key components. First, the government has published regulatory guidance that clarifies how existing UK medicines and spaceflight frameworks apply to space-manufactured pharmaceuticals. Second, case studies will provide companies with real-world examples of the approval process. Third, the CAA is launching a ‘Re-entry Regulatory Sandbox’—a controlled testing environment that will streamline the licensing of platforms returning manufactured products to Earth. Fourth, regulators are strengthening supply-chain engagement to identify and address practical obstacles to commercialisation.

The government is backing these regulatory advances with substantial investment. The National Space Innovation Programme has allocated £2.2 million in funding to support emerging technologies linked to in-orbit manufacturing, including microgravity research laboratories and bio-manufacturing platforms.

A prominent beneficiary is BioOrbit, a pioneering UK company developing a scalable system to crystallise biologic drugs in space. The MHRA has funded BioOrbit’s PHARM (Pharmaceuticals in Orbit Research Mission) project with £250,000. The feasibility study, running until March 2026, will serve as a critical test case demonstrating how existing UK pharmaceutical regulations apply to extra-terrestrial environments. BioOrbit is focusing specifically on creating more precise protein crystals for cancer treatments that could be manufactured in space and administered to patients at home.

“Space-made pharmaceuticals will have a dramatic impact on all of our lives,” said Dr Katie King, Chief Executive of BioOrbit. “BioOrbit’s PHARM study ensures that we can produce drugs in space under the same regulation as drugs made on Earth—which will be a world first.”

The government is also investing in enabling infrastructure. Grants have been awarded to companies including Frontier Space Technologies to expand microgravity research capabilities through its SpaceLab platform, supporting pharmaceutical development and drug discovery. Additional funding has been directed towards Biologic Technologies to develop a ‘Space Biocomputer’ designed to enable bio-manufacturing capabilities for products such as RNA medicines.

This initiative forms part of the UK Government’s £2 billion Life Sciences Sector Plan and reflects the government’s strategic focus on space-enabled industries. Recent demonstration missions, including Space Forge’s ForgeStar 1 and Astroscale UK’s ELSA-D satellite servicing mission, have proven the UK’s ability to license and operate novel space technologies. These successful projects demonstrate that in-orbit manufacturing is no longer speculative science but an operational reality.

Space Minister Liz Lloyd emphasised the practical significance of the announcement: “The UK is taking medical breakthroughs from orbit to patient—tackling the practical barriers that have held back commercial in-orbit manufacturing, from regulatory uncertainty to supply chain gaps.”

Lord David Willetts, Chair of the UK Space Agency and Regulatory Innovation Office, added: “In-orbit manufacturing of pharmaceuticals represents a significant opportunity for the UK, combining the growth potential of our space sector with the promise of better treatments for patients. Setting out a clear adoption pathway with well-defined regulatory requirements gives investors and entrepreneurs the confidence they need to bring these innovations to market.”

Key Takeaways

• The UK has announced a world-first regulatory roadmap enabling pharmaceuticals manufactured in space to be brought safely to patients, removing barriers that previously held back this sector
• The MHRA, UK Space Agency, CAA and RIO have coordinated to provide regulatory clarity, guidance, case studies and a ‘regulatory sandbox’ for companies developing space-based medicines
• The government has invested £2.2 million through its National Space Innovation Programme, with BioOrbit receiving £250,000 to develop systems for manufacturing cancer drugs in microgravity

What This Means for Kent Residents

For patients across Kent and Medway, this regulatory framework could eventually lead to access to new and more effective treatments, particularly for cancer and other complex diseases requiring biologic medicines. Whilst space-manufactured drugs are still in development, the clarity this roadmap provides means companies are more likely to invest in bringing these treatments to market. Patients seeking information about accessing new treatments through the NHS should discuss options with their GP or specialist consultant. The Kent and Medway NHS Trust and local cancer services will be kept informed as these medicines progress through regulatory approval and become available for prescription. This innovation reflects the broader British investment in life sciences that aims to improve healthcare outcomes and ensure the NHS can access cutting-edge treatments for its patients.